Drug Profile
Descartes 08
Alternative Names: Anti-BCMA CAR-T cell therapy - Cartesian Therapeutics; Anti-BCMA chimeric antigen receptor T cell therapy - Cartesian Therapeutics; Descartes-08Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Cartesian Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Autoimmune disorders; Multiple myeloma; Neurological disorders; Systemic lupus erythematosus
- Phase I/II Myasthenia gravis